AnGesTSE:4563 +6.12%53 EBITDA Margin % is -679.41% as of Dec. 2025. GuruFocus rates TSE:4563 with a GF Score™ of 53/100 and a GF Value™ of 円96.12 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 935 Biotechnology companies, AnGes ranks worse than 72.51% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. AnGes's EBITDA for the
three
months ended in Dec. 2025 was 円-1,549.0 Mil. AnGes's Revenue for the
three
months ended in Dec. 2025 was 円228.0 Mil. Therefore, AnGes's EBITDA margin for the quarter that ended in Dec. 2025 was -679.41%.
AnGes (TSE:4563) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
AnGes EBITDA Margin % Related Terms
AnGes EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for AnGes's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:4563 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, AnGes's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
AnGes EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, AnGes's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where AnGes's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AnGes (TSE:4563) has a EBITDA Margin % of -679.41% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on AnGes and its competitors. According to the industry distribution chart, AnGes ranks #678 out of 935 companies in the Biotechnology industry, placing it in the top 72.5%.
Is AnGes' EBITDA Margin % too high?
AnGes' current EBITDA Margin % is -679.41%. Based on the distribution chart, AnGes ranks #678 out of 935 companies in the Biotechnology industry, which is below the industry midpoint. Overall, AnGes has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does AnGes' EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, AnGes ranks #678 out of 935 companies for EBITDA Margin %. This places AnGes in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on AnGes and its competitors. AnGes's current EBITDA Margin % is -679.41%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AnGes stock overvalued right now?
Based on GuruFocus' analysis, AnGes (TSE:4563) is currently considered Possible Value Trap. The stock's GF Value™ is 円96.12, compared to a current price of 円52.00 — trading 45.9% below its estimated fair value. The current EBITDA Margin % is -679.41%. AnGes' overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For AnGes (TSE:4563), the current EBITDA Margin % is -679.41% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is AnGes (TSE:4563) Overvalued in 2026?
Based on GuruFocus' analysis, AnGes stock appears to be undervalued.
The current stock price of 円52.00 is trading 45.9% below its estimated GF Value™ of 円96.12.
GuruFocus considers AnGes to be Possible Value Trap.
Key valuation signals for TSE:4563:
EBITDA Margin %: -679.41%
GF Value™: 円96.12 vs. price of 円52.00 (45.9% below fair value)
No single metric tells the full story. See the TSE:4563 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
AnGes Inc is a biopharmaceutical company. The company is involved in research and development and sales of pharmaceuticals such as gene-based drugs (gene therapy products, nucleic acid drugs); contract testing for rare genetic diseases, etc.
53GF Score
Get the complete analysis for TSE:4563
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4563 has been successfully added to your 
